Biotechnology and healthcare is decade's top performing sector

Investors gain 491 per cent return, far outstripping average for past ten years

                                

Biotechnology and Healthcare was the top performing investment company sector of the last decade, according to new data from the Association of Investment Companies (AIC).

Over the past ten years the sector produced a 491 per cent return compared with a return of 198 per cent for the average investment company over the same period.

Investment companies focused on smaller companies also delivered strong returns. The UK Smaller Companies and Global Smaller Companies sectors were the second and third best performing sectors of the decade and delivered 379 per cent and 330 per cent respectively.

European Smaller Companies also featured in the top ten.

Top performing investment companies of the decade

The 10 best performing AIC member investment companies over the past decade came from a variety of sectors, but companies in the UK Smaller Companies sector featured most strongly, making four appearances in the top ten.

Volta Finance was the best performing member company over the decade. The company from the Debt Structured Finance sector produced an impressive 959 per cent share price total return from 1 January 2010 to 31 December 2019.

It was followed by Lindsell Train in the Global sector, up 730 per cent and Baillie Gifford Shin Nippon from the Japanese Smaller Companies sector, up 678 per cent over the same period.

RECOMMENDED READING: Market predictions: will 2020 bring riches or a recession?

Annabel Brodie-Smith, Communications Director of the Association of Investment Companies (AIC), said: “It’s encouraging to see a diverse spectrum of investment company sectors perform so strongly over the last decade. While Biotechnology & Healthcare was the top performing sector by some margin, two UK equity sectors made it into the top ten despite the Brexit referendum and subsequent lack of clarity surrounding the UK’s exit.”

RECOMMENDED READING: CRISPR Therapeutics share price surges

The material provided on this website is for information purposes only and should not be regarded as investment research or investment advice. Any opinion that may be provided on this page is a subjective point of view of the author and does not constitute a recommendation by Currency Com Bel LLC or its partners. We do not make any endorsements or warranty on the accuracy or completeness of the information that is provided on this page. By relying on the information on this page, you acknowledge that you are acting knowingly and independently and that you accept all the risks involved.
iPhone Image
Trade the world’s top tokenised stocks, indices, commodities and currencies with the help of crypto or fiat
iMac Image
Trade the world’s top tokenised stocks, indices, commodities and currencies with the help of crypto or fiat
iMac Image